Three’s A Crowd: Cimzia Joins Humira, Remicade For Crohn’s Disease

UCB is pushing pricing and other incentives for Cimzia (certolizumab) - rather than clinical benefit - to break into a crowded Crohn's disease market that already includes two well-established tumor necrosis factor inhibitors

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet